{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T05:49:23Z","timestamp":1745819363898},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,28]]},"DOI":"10.7759\/cureus.44296","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T04:45:20Z","timestamp":1693284320000},"source":"Crossref","is-referenced-by-count":1,"title":["Immune Checkpoint Inhibitor-Induced Endocrine Adverse Events in Cancer Patients at a Tertiary Care Center in Saudi Arabia"],"prefix":"10.7759","author":[{"given":"Ali","family":"Alqahtani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lamia","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulmohsen","family":"Alghassab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mussa","family":"Almalki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2020-0827","article-title":"Endocrine complications of immunotherapies: a review","volume":"21","author":"Hattersley R","year":"2021","unstructured":"Hattersley R, Nana M, Lansdown AJ. Endocrine complications of immunotherapies: a review. Clin Med (Lond). 2021, 21:e212-22. 10.7861\/clinmed.2020-0827","journal-title":"Clin Med (Lond)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2174\/156800961506150805145120","article-title":"Immune checkpoint inhibitors for cancer therapy: clinical efficacy and safety","volume":"15","author":"Azoury SC","year":"2015","unstructured":"Azoury SC, Straughan DM, Shukla V. Immune checkpoint inhibitors for cancer therapy: clinical efficacy and safety. Curr Cancer Drug Targets. 2015, 15:452-62. 10.2174\/156800961506150805145120","journal-title":"Curr Cancer Drug Targets"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: review and management of endocrine adverse events","volume":"21","author":"Gonz\u00e1lez-Rodr\u00edguez E","year":"2016","unstructured":"Gonz\u00e1lez-Rodr\u00edguez E, Rodr\u00edguez-Abreu D. Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist. 2016, 21:804-16. 10.1634\/theoncologist.2015-0509","journal-title":"Oncologist"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.371","article-title":"CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations","volume":"4","author":"Camacho LH","year":"2015","unstructured":"Camacho LH. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. Cancer Med. 2015, 4:661-72. 10.1002\/cam4.371","journal-title":"Cancer Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0002","article-title":"Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges","volume":"8","author":"Kyi C","year":"2016","unstructured":"Kyi C, Postow MA. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy. 2016, 8:821-37. 10.2217\/imt-2016-0002","journal-title":"Immunotherapy"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel SP","year":"2023","unstructured":"Patel SP, Othus M, Chen Y, et al.. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023, 388:813-23. 10.1056\/NEJMoa2211437","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette J","year":"2019","unstructured":"de Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res. 2019, 51:145-56. 10.1055\/a-0843-3366","journal-title":"Horm Metab Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1094-2","article-title":"Clinical development of targeted and immune based anti-cancer therapies","volume":"38","author":"Seebacher NA","year":"2019","unstructured":"Seebacher NA, Stacy AE, Porter GM, Merlot AM. Clinical development of targeted and immune based anti-cancer therapies. J Exp Clin Cancer Res. 2019, 38:156. 10.1186\/s13046-019-1094-2","journal-title":"J Exp Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja L","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017, 28:2377-85. 10.1093\/annonc\/mdx286","journal-title":"Ann Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.836859","article-title":"Immune checkpoint inhibitor-induced hypophysitis and patterns of loss of pituitary function","volume":"12","author":"Jessel S","year":"2022","unstructured":"Jessel S, Weiss SA, Austin M, et al.. Immune checkpoint inhibitor-induced hypophysitis and patterns of loss of pituitary function. Front Oncol. 2022, 12:836859. 10.3389\/fonc.2022.836859","journal-title":"Front Oncol"},{"key":"ref11","unstructured":"US Department of Health and Human Sciences. Common terminology criteria for adverse events (CTCAE) version 5.0. Accessed: August 29, 2023: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0358","article-title":"Endocrine side effects of cancer immunotherapy","volume":"24","author":"Cukier P","year":"2017","unstructured":"Cukier P, Santini FC, Scaranti M, Hoff AO. Endocrine side effects of cancer immunotherapy. Endocr Relat Cancer. 2017, 24:T331-47. 10.1530\/ERC-17-0358","journal-title":"Endocr Relat Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen JB","year":"2018","unstructured":"Haanen JB, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018, 29:iv264-6. 10.1093\/annonc\/mdy162","journal-title":"Ann Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins F","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, et al.. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019, 16:563-80. 10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright JJ","year":"2021","unstructured":"Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021, 17:389-99. 10.1038\/s41574-021-00484-3","journal-title":"Nat Rev Endocrinol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam A","year":"2019","unstructured":"Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019, 2:e192535. 10.1001\/jamanetworkopen.2019.2535","journal-title":"JAMA Netw Open"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0470","article-title":"Endocrine-related adverse events related to immune checkpoint inhibitors: proposed algorithms for management","volume":"25","author":"Del Rivero J","year":"2020","unstructured":"Del Rivero J, Cordes LM, Klubo-Gwiezdzinska J, Madan RA, Nieman LK, Gulley JL. Endocrine-related adverse events related to immune checkpoint inhibitors: proposed algorithms for management. Oncologist. 2020, 25:290-300. 10.1634\/theoncologist.2018-0470","journal-title":"Oncologist"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa R","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:173-82. 10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0342","article-title":"Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review","volume":"9","author":"Stelmachowska-Bana\u015b M","year":"2020","unstructured":"Stelmachowska-Bana\u015b M, Czajka-Oraniec I. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review. Endocr Connect. 2020, 9:R207-28. 10.1530\/EC-20-0342","journal-title":"Endocr Connect"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber JS","year":"2012","unstructured":"Weber JS, K\u00e4hler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012, 30:2691-7. 10.1200\/JCO.2012.41.6750","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber JS","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD, et al.. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017, 35:785-92. 10.1200\/JCO.2015.66.1389","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder M","year":"2014","unstructured":"Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014, 21:371-81. 10.1530\/ERC-13-0499","journal-title":"Endocr Relat Cancer"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","author":"de Filette J","year":"2016","unstructured":"de Filette J, Jansen Y, Schreuer M, Everaert H, Velkeniers B, Neyns B, Bravenboer B. Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab. 2016, 101:4431-9. 10.1210\/jc.2016-2300","journal-title":"J Clin Endocrinol Metab"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang LS","year":"2019","unstructured":"Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev. 2019, 40:17-65. 10.1210\/er.2018-00006","journal-title":"Endocr Rev"},{"key":"ref25","article-title":"Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification","volume":"28","author":"Rastrelli M","year":"2014","unstructured":"Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014, 28:1005-11.","journal-title":"In Vivo"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot JM","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, et al.. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016, 54:139-48. 10.1016\/j.ejca.2015.11.016","journal-title":"Eur J Cancer"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0169","article-title":"Management of endocrine disease: immune check point inhibitors-induced hypophysitis","volume":"181","author":"Albarel F","year":"2019","unstructured":"Albarel F, Castinetti F, Brue T. Management of endocrine disease: immune check point inhibitors-induced hypophysitis. Eur J Endocrinol. 2019, 181:R107-18. 10.1530\/EJE-19-0169","journal-title":"Eur J Endocrinol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye ES","year":"2022","unstructured":"Husebye ES, Castinetti F, Criseno S, et al.. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022, 187:G1-G21. 10.1530\/EJE-22-0689","journal-title":"Eur J Endocrinol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli P","year":"2016","unstructured":"Caturegli P, Di Dalmazi G, Lombardi M, et al.. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol. 2016, 186:3225-35. 10.1016\/j.ajpath.2016.08.020","journal-title":"Am J Pathol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje AT","year":"2014","unstructured":"Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, Nachtigall L. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014, 99:4078-85. 10.1210\/jc.2014-2306","journal-title":"J Clin Endocrinol Metab"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0810","article-title":"The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma","volume":"178","author":"Scott ES","year":"2018","unstructured":"Scott ES, Long GV, Guminski A, Clifton-Bligh RJ, Menzies AM, Tsang VH. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. Eur J Endocrinol. 2018, 178:173-80. 10.1530\/EJE-17-0810","journal-title":"Eur J Endocrinol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01905","article-title":"Anti-PD-L1 treatment induced central diabetes insipidus","volume":"103","author":"Zhao C","year":"2018","unstructured":"Zhao C, Tella SH, Del Rivero J, et al.. Anti-PD-L1 treatment induced central diabetes insipidus. J Clin Endocrinol Metab. 2018, 103:365-9. 10.1210\/jc.2017-01905","journal-title":"J Clin Endocrinol Metab"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-018-0073-4","article-title":"Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports","volume":"5","author":"Tan MH","year":"2019","unstructured":"Tan MH, Iyengar R, Mizokami-Stout K, et al.. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clin Diabetes Endocrinol. 2019, 5:1. 10.1186\/s40842-018-0073-4","journal-title":"Clin Diabetes Endocrinol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje A","year":"2016","unstructured":"Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary. 2016, 19:82-92. 10.1007\/s11102-015-0671-4","journal-title":"Pituitary"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2014.06.011","article-title":"Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis","volume":"125","author":"Chodakiewitz Y","year":"2014","unstructured":"Chodakiewitz Y, Brown S, Boxerman JL, Brody JM, Rogg JM. Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis. Clin Neurol Neurosurg. 2014, 125:125-30. 10.1016\/j.clineuro.2014.06.011","journal-title":"Clin Neurol Neurosurg"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment","volume":"14","author":"Di Dalmazi G","year":"2019","unstructured":"Di Dalmazi G, Ippolito S, Lupi I, Caturegli P. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. Expert Rev Endocrinol Metab. 2019, 14:381-98. 10.1080\/17446651.2019.1701434","journal-title":"Expert Rev Endocrinol Metab"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1465","article-title":"Increased reporting of immune checkpoint inhibitor-associated diabetes","volume":"41","author":"Wright JJ","year":"2018","unstructured":"Wright JJ, Salem JE, Johnson DB, et al.. Increased reporting of immune checkpoint inhibitor-associated diabetes. Diabetes Care. 2018, 41:e150-1. 10.2337\/dc18-1465","journal-title":"Diabetes Care"},{"key":"ref38","article-title":"Immune Checkpoint Inhibitors Related Endocrine Adverse Events","author":"Ghada Elshimy","year":"2021","unstructured":"Ghada Elshimy, Rishi Raj, Halis Kaan Akturk, et al.. Immune Checkpoint Inhibitors Related Endocrine Adverse Events. Endotext, 2021."},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0528-x","article-title":"Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma","volume":"7","author":"Trinh B","year":"2019","unstructured":"Trinh B, Sanchez GO, Herzig P, L\u00e4ubli H. Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma. J Immunother Cancer. 2019, 7:52. 10.1186\/s40425-019-0528-x","journal-title":"J Immunother Cancer"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00076","article-title":"Autoimmune-related primary hypoparathyroidism possibly induced by the administration of pembrolizumab: a case report","volume":"14","author":"Umeguchi H","year":"2018","unstructured":"Umeguchi H, Takenoshita H, Inoue H, et al.. Autoimmune-related primary hypoparathyroidism possibly induced by the administration of pembrolizumab: a case report. J Oncol Pract. 2018, 14:449-51. 10.1200\/JOP.18.00076","journal-title":"J Oncol Pract"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7459268","article-title":"Hypocalcemia with immune checkpoint inhibitors: the disparity among various reports","volume":"2020","author":"Nalluru SS","year":"2020","unstructured":"Nalluru SS, Piranavan P, Ning Y, Ackula H, Siddiqui AD, Trivedi N. Hypocalcemia with immune checkpoint inhibitors: the disparity among various reports. Int J Endocrinol. 2020, 2020:7459268. 10.1155\/2020\/7459268","journal-title":"Int J Endocrinol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma","volume":"35","author":"Sznol M","year":"2017","unstructured":"Sznol M, Ferrucci PF, Hogg D, et al.. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol. 2017, 35:3815-22. 10.1200\/JCO.2016.72.1167","journal-title":"J Clin Oncol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang DY","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al.. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:1721-8. 10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0320","article-title":"French Endocrine Society Guidance on endocrine side effects of immunotherapy","volume":"26","author":"Castinetti F","year":"2019","unstructured":"Castinetti F, Albarel F, Archambeaud F, et al.. French Endocrine Society Guidance on endocrine side effects of immunotherapy. Endocr Relat Cancer. 2019, 26:G1-G18. 10.1530\/ERC-18-0320","journal-title":"Endocr Relat Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/179915-immune-checkpoint-inhibitor-induced-endocrine-adverse-events-in-cancer-patients-at-a-tertiary-care-center-in-saudi-arabia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:56:13Z","timestamp":1707508573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/179915-immune-checkpoint-inhibitor-induced-endocrine-adverse-events-in-cancer-patients-at-a-tertiary-care-center-in-saudi-arabia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.44296","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,28]]}}}